Ocumension Invests $15.7 Million In EyePoint of the US
January 04, 2021 at 06:37 AM EST
Shanghai 's Ocumension Therapeutics invested $15.7 million in its US partner, EyePoint Pharma of Massachusetts . Previously, Ocumension acquired China rights to EyePoint's two commercial products: Yutiq®, a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and Dexycu®, a postoperative inflammation treatment following ocular surgery. In July, Ocumension completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. More details.... Stock Symbols: (HK: 1477) (NSDQ: EYPT) Share this with colleagues: // //
